These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24296982)

  • 1. Idiopathic pulmonary fibrosis: recent trials and current drug therapy.
    Jones MG; Fletcher S; Richeldi L
    Respiration; 2013; 86(5):353-63. PubMed ID: 24296982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.
    Collard HR; Bradford WZ; Cottin V; Flaherty KR; King TE; Koch GG; Kolb M; Martinez FJ; Montgomery B; Raghu G; Richeldi L; Rose D; Wells AU; Brown KK
    Eur Respir J; 2015 Jul; 46(1):243-9. PubMed ID: 25900377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The big clinical trials in idiopathic pulmonary fibrosis.
    Luppi F; Spagnolo P; Cerri S; Richeldi L
    Curr Opin Pulm Med; 2012 Sep; 18(5):428-32. PubMed ID: 22759771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical trials for the treatment of idiopathic pulmonary fibrosis.
    Klingsberg RC; Mutsaers SE; Lasky JA
    Respirology; 2010 Jan; 15(1):19-31. PubMed ID: 20199632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment.
    Homma S; Sugino K; Sakamoto S
    Respir Investig; 2015 Jan; 53(1):7-12. PubMed ID: 25542598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis].
    Bonella F; Wessendorf TE; Costabel U
    Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications.
    Spagnolo P; Rossi G; Cavazza A
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1005-17. PubMed ID: 24953006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.
    Vancheri C; du Bois RM
    Eur Respir J; 2013 Feb; 41(2):262-9. PubMed ID: 22903965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis.
    Nathan SD; Martinez FJ
    Curr Opin Pulm Med; 2017 Sep; 23(5):426-431. PubMed ID: 28771451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research.
    Baroke E; Gauldie J; Kolb M
    Expert Rev Respir Med; 2013 Oct; 7(5):465-78. PubMed ID: 24138691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.
    O'Riordan TG; Smith V; Raghu G
    Chest; 2015 Oct; 148(4):1083-1092. PubMed ID: 26020856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for idiopathic pulmonary fibrosis.
    Selman M; Pardo A; Richeldi L; Cerri S
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):341-62. PubMed ID: 21410428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.